Key Takeaways
- Interim ALPHA3 data revealed 58.3% MRD negativity for cema-cel versus 16.7% for observation alone
- Zero cases of cytokine release syndrome or neurotoxicity reported among treated participants
- Baird upgraded its ALLO price target from $7.00 to $9.00 while maintaining Outperform status
- The firm’s probability of success forecast for the therapy increased to 70%
- Shares climbed to $3.87 from $2.91, marking approximately 99% gains year-to-date
Shares of Allogene Therapeutics experienced a remarkable surge exceeding 41% on April 13, 2026, following the disclosure of encouraging interim results from the company’s pivotal Phase 2 ALPHA3 clinical trial. The study is examining cemacabtagene ansegedleucel (cema-cel) as a treatment option for patients with high-risk large B-cell lymphoma.
Allogene Therapeutics, Inc., ALLO
The released information came from an interim futility assessment. Among the initial cohort of 24 randomized participants, the cema-cel treatment group achieved minimal residual disease (MRD) negativity in 58.3% of cases. By contrast, the observation-only group saw just 16.7% reach this milestone — representing a substantial gap of 41.6 percentage points.
Researchers are utilizing Natera’s investigational CLARITY MRD assay to detect high-risk patients prior to observable clinical relapse. The therapy is being assessed as a first-line consolidation treatment, positioning it earlier in the therapeutic sequence compared to most existing CAR T methodologies.
Remarkable Safety Results Capture Market Interest
The safety outcomes proved equally compelling as the effectiveness metrics. Remarkably, none of the participants receiving treatment developed cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome — two complications frequently linked with CAR T therapeutic interventions.
No treatment-related serious adverse events were documented. Such a favorable safety record is uncommon within this therapeutic category, and Baird identified this as a key distinguishing characteristic when evaluating cema-cel against second-line autologous CAR T alternatives.
The therapy’s potential for outpatient administration, coupled with the favorable safety data, contributes to what may make this program particularly noteworthy. Current CAR T treatments typically necessitate inpatient care and carry more significant toxicity concerns.
Following the data announcement, Baird elevated its price objective for ALLO from $7.00 to $9.00 while retaining its Outperform recommendation. The investment firm also increased its probability of success projection for the program to 70%.
“The limited dataset size of 12 treated patients should generate enthusiasm,” Baird wrote, acknowledging the early-stage nature of the readout while flagging the initial results as a positive signal for the commercial profile in the first-line setting.
Future Milestones and Timeline
The ALPHA3 clinical study is currently recruiting approximately 220 participants across more than 60 research locations. Efficacy measurements remain blinded during this phase, and the current dataset represents early-stage findings. The statistical validity will need confirmation as enrollment progresses and data matures.
Scheduled interim event-free survival evaluations are anticipated in 2027, with complete primary outcome data projected for 2028. Favorable results from these analyses could provide the foundation for a subsequent biologics license application submission.
The investment community is taking notice beyond Baird. Jefferies recently launched coverage of ALLO with a Buy recommendation and established a $6.00 price objective, while Citizens reaffirmed its Market Outperform stance with a $5.00 target price.
On April 13, ALLO shares reached $3.87, advancing from the previous session’s close of $2.91. The stock has appreciated roughly 99% since the start of the year and is currently trading near its 52-week peak. According to InvestingPro analysis, the stock is presently valued above its calculated fair value, though the company maintains a balance sheet with cash holdings exceeding its debt obligations.
